These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26187018)

  • 21. Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia.
    Khosrovaneh A; Riederer K; Saeed S; Tabriz MS; Shah AR; Hanna MM; Sharma M; Johnson LB; Fakih MG; Khatib R
    Clin Infect Dis; 2004 May; 38(9):1328-30. PubMed ID: 15127350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of tolerance in cloxacillin prophylaxis of experimental Staphylococcus aureus endocarditis.
    Voorn GP; Thompson J; Goessens WH; Schmall-Bauer W; Broeders PH; Michel MF
    J Infect Dis; 1992 Jul; 166(1):169-73. PubMed ID: 1607692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of vancomycin minimum inhibitory concentration on clinical outcomes of patients with vancomycin-susceptible Staphylococcus aureus infections: a meta-analysis and meta-regression.
    Mavros MN; Tansarli GS; Vardakas KZ; Rafailidis PI; Karageorgopoulos DE; Falagas ME
    Int J Antimicrob Agents; 2012 Dec; 40(6):496-509. PubMed ID: 23068600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG; Basuino L; Chambers HF
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in vancomycin minimum inhibitory concentrations for Staphylococcus aureus obtained with the automated Phoenix™ system, the Clinical and Laboratory Standards Institute broth microdilution method and the standard Etest.
    Muñoz-Cobo B; Sancho-Tello S; Costa E; Bravo D; Torregrosa I; de Lomas JG; Navarro D
    Int J Antimicrob Agents; 2011 Mar; 37(3):278-9. PubMed ID: 21269809
    [No Abstract]   [Full Text] [Related]  

  • 26. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
    Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Aug; 46(33):765-6. PubMed ID: 9272582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.
    Gomes DM; Ward KE; LaPlante KL
    Pharmacotherapy; 2015 Apr; 35(4):424-32. PubMed ID: 25884530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.
    Asseray N; Jacqueline C; Le Mabecque V; Batard E; Bugnon D; Potel G; Caillon J
    Antimicrob Agents Chemother; 2005 Feb; 49(2):857-9. PubMed ID: 15673789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Occurrence of a USA300 vancomycin-intermediate Staphylococcus aureus.
    Hageman JC; Patel J; Franklin P; Miscavish K; McDougal L; Lonsway D; Khan FN
    Diagn Microbiol Infect Dis; 2008 Dec; 62(4):440-2. PubMed ID: 18842378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paradoxical dose effect of continuously administered cloxacillin in treatment of tolerant Staphylococcus aureus endocarditis in rats.
    Voorn GP; Thompson J; Goessens WH; Schmal-Bauer WC; Broeders PH; Michel MF
    J Antimicrob Chemother; 1994 Mar; 33(3):585-93. PubMed ID: 8040122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High vancomycin MICs within the susceptible range in Staphylococcus aureus bacteraemia isolates are associated with increased cell wall thickness and reduced intracellular killing by human phagocytes.
    Falcón R; Martínez A; Albert E; Madrid S; Oltra R; Giménez E; Soriano M; Vinuesa V; Gozalbo D; Gil ML; Navarro D
    Int J Antimicrob Agents; 2016 May; 47(5):343-50. PubMed ID: 27056298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gentamicin may have no effect on mortality of staphylococcal prosthetic valve endocarditis.
    Ramos-Martínez A; Muñoz Serrano A; de Alarcón González A; Muñoz P; Fernández-Cruz A; Valerio M; Fariñas MC; Gutiérrez-Cuadra M; Miró JM; Ruiz-Morales J; Sousa-Regueiro D; Montejo JM; Gálvez-Acebal J; HidalgoTenorio C; Domínguez F;
    J Infect Chemother; 2018 Jul; 24(7):555-562. PubMed ID: 29628387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin.
    Fortún J; Navas E; Martínez-Beltrán J; Pérez-Molina J; Martín-Dávila P; Guerrero A; Moreno S
    Clin Infect Dis; 2001 Jul; 33(1):120-5. PubMed ID: 11389505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of tolerance in cloxacillin treatment of experimental Staphylococcus aureus endocarditis.
    Voorn GP; Thompson J; Goessens WH; Schmal-Bauer W; Broeders PH; Michel MF
    J Infect Dis; 1991 Mar; 163(3):640-3. PubMed ID: 1995736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interim guidelines for prevention and control of Staphylococcal infection associated with reduced susceptibility to vancomycin.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Jul; 46(27):626-8, 635. PubMed ID: 9218649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Right endocarditis caused by Staphylococcus aureus in parenteral drug addicts: evaluation of a combined therapeutic scheme for 2 weeks versus conventional treatment].
    Espinosa FJ; Valdés M; Martín-Luengo F; Arribas JP; Albaladejo J; Pérez-Gracia A; García-Henarejos JA; Martínez-Madrid O; García-Alberola A
    Enferm Infecc Microbiol Clin; 1993 May; 11(5):235-40. PubMed ID: 8324018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update: Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Sep; 46(35):813-5. PubMed ID: 9310213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of in vitro susceptibility phenotype against thrombin-induced platelet microbicidal protein on treatment and prophylaxis outcomes of experimental Staphylococcus aureus endocarditis.
    Dhawan VK; Yeaman MR; Bayer AS
    J Infect Dis; 1999 Nov; 180(5):1561-8. PubMed ID: 10515816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus.
    Lodise TP; McKinnon PS; Levine DP; Rybak MJ
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3731-3. PubMed ID: 17664322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.